Cardiogenic ShockNCT06127927
An Interventional Left Ventricular Assist System for Cardiogenic Shock
A study testing Interventional Left Ventricular Assist System in people with Cardiogenic Shock, run by Fujian Medical University at 2 sites in China.
Trial summary
Imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling Bionic Technology Co., Ltd. has developed an interventional left ventricular assist system. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Cardiogenic Shock
- What is being tested?
- Interventional Left Ventricular Assist System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 2 sitesChina
- Study dates
- 8 Nov 2023to 8 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-75 years old;
- Refractory cardiogenic shock as determined by the cardiac MDT expert group; The criteria for refractory cardiogenic shock are: despite adequate doses of two vasoactive drugs and treatment of the underlying cause, there is still evidence of tissue hypoperfusion;
- The subject can understand the purpose of the trial, voluntarily participate and sign the written informed consent form reviewed and approved by the ethics committee; the subject agrees to complete the follow-up in accordance with the protocol requirements.
- Age 18-75 years old;
- Low cardiac output syndrome or increased filling pressure after regular continuous pumping of 1 high-dose or 2 medium-dose inotropic drugs within 48 hours after cardiopulmonary bypass was removed during cardiac surgery. The specific criteria are as follows;
- The drugs, doses and time of 1 high-dose or 2 medium-dose inotropic drugs are as follows:
Show all 9Show fewer
- Epinephrine: medium dose (<0.03 μg/kg/min), continuous pumping ≥15 minutes High dose (≥0.03 μg/kg/min), continuous pumping ≥15 minutes; Dobutamine: medium dose (<5μg/kg/min), continuous pumping ≥15 minutes High dose (≥5μg/kg/min), continuous pumping ≥15 minutes; Milrinone: medium dose (<0.3 μg/kg/min), continuous pumping ≥120 minutes High dose (≥0.3 μg/kg/min), continuous pumping ≥120 minutes; Low cardiac output syndrome: cardiac index 1.3≤CI≤2.2 L/min/m2;
- Increased filling pressure: pulmonary capillary wedge pressure:
- 20≤PCWP≤30mmHg or pulmonary artery systolic pressure: 25≤PAP≤35mmHg 3) The subject can understand the purpose of the trial, voluntarily participate and sign the informed consent form reviewed and approved by the ethics committee; the subject agrees to complete the follow-up in accordance with the protocol requirements.
Who cannot join
- Right heart failure that meets any of the following conditions:
- a Central venous pressure-capillary wedge pressure ≥10mmHg; b Central venous pressure-pulmonary artery diastolic pressure ≥10mmHg; c Cardiac tamponade.
- Any peripheral vascular disease that prevents the placement of the trial device;
- Left or right ventricular thrombus;
- Aortic valve regurgitation, echocardiographic grade ≥2+;
- Aortic valve stenosis, valve area ≤1.5cm2;
Show all 50Show fewer
- Aortic valve calcification;
- Presence of mechanical aortic valve;
- Hypertrophic or obstructive cardiomyopathy;
- Untreated ventricular septal or atrial septal defect;
- Patent foramen ovale;
- Mechanical complications of acute myocardial infarction;
- Presence of hereditary spherocytosis, hereditary elliptocytosis, autoimmune hemolytic anemia or other diseases that cause hemolysis;
- Cardiopulmonary resuscitation lasting more than 15 minutes within 24 hours before catheter pump implantation;
- Ventricular tachycardia or ventricular fibrillation is ineffective with drug treatment;
- Renal failure, serum creatinine ≥309.4umol/l or blood urea nitrogen ★ ≥35.7mmol/l);
- Liver failure (total bilirubin ≥85.5umol/l);
- Allergy or intolerance to heparin;
- Presence of any cardiac assist device;
- Presence of active systemic infection;
- Refusing to sign the informed consent form or failing to complete follow-up as required by the protocol;
- Pregnant or lactating women, female subjects with potential fertility but unable or unwilling to use effective contraceptive measures during the study;
- Subjects who have participated in other clinical trials within 3 months or are currently participating in other clinical trials;
- Other situations that the investigator believes are not suitable for clinical trials.
- For Formal Research Phase
- Right heart failure that meets any of the following conditions:
- Central venous pressure-capillary wedge pressure ≥10mmHg;
- Central venous pressure-pulmonary artery diastolic pressure ≥10mmHg;
- Cardiac ascites.
- Any peripheral vascular disease that prevents the placement of the trial device;
- Left or right ventricular thrombus;
- Aortic valve regurgitation, echocardiographic grade ≥2+;
- Aortic valve stenosis, valve area ≤1.5cm2;
- Presence of mechanical aortic valve;
- Hypertrophic or obstructive cardiomyopathy;
- Untreated ventricular septal or atrial septal defect;
- Patent foramen ovale;
- Mechanical complications of acute myocardial infarction;
- Suffering from diseases that cause increased blood cell fragility or hemolysis;
- Cardiopulmonary resuscitation lasting more than 15 minutes within 24 hours before catheter pump implantation;
- Sustained or non-sustained ventricular tachycardia or ventricular fibrillation that is unresponsive to drug treatment;
- Renal failure, serum creatinine ≥3.5mg/dl or blood urea nitrogen ≥100mg/dl;
- Liver failure, total bilirubin ≥5mg/dl;
- Allergy or intolerance to heparin;
- Other cardiac assist devices other than IABP have been implanted;
- Active systemic infection;
- Refuse to sign the informed consent form or fail to complete follow-up as required by the protocol;
- Pregnant or lactating women, female subjects with potential fertility but unable or unwilling to use effective contraceptive measures during the study;
- Subjects who are participating in other clinical trials and have not yet reached the endpoints of the trial;
- Other situations that the investigator believes are not suitable for clinical trials.
Trial locations and contacts
2 sites in 1 country.
China2 sites, 2 recruiting
- Recruiting
Department of Cardiovascular Surgery
Fuzhou, Fujian, 350001
Liang-Wan Chen, M.D, Ph.D, 86 13358255333, daixiaofu719@hotmail.com
E Lin, M.D, 86 13365912195, 1470054258@qq.com
- Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001
Liang-wan Chen, PhD MD, 13358255333, chenliangwan@tom.com
About this study
Official title: Evaluation the Efficacy and Safety of an Interventional Left Ventricular Assist System for Hemodynamic Support in Patients With Cardiogenic Shock: A Prospective, Multicenter, Single-group Target Value Study of Sustained
Imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling Bionic Technology Co., Ltd. has developed an interventional left ventricular assist system. The test device was tested in preclinical animals It has shown good effectiveness and safety. Through the implementation of this clinical trial, the interventional left ventricular assist system The safety and effectiveness of the system for hemodynamic support in patients with cardiogenic shock have led to further development of this product in the country.
Read the detailed description
In recent years, patients with severe heart disease, with coronary heart disease as the main disease spectrum, have been on the rise, and the mortality rate remains high. In routine clinical diagnosis and treatment, inotropic drugs and vasoactive drugs are used to correct shock and maintain blood flow. The cornerstone of mechanical stability, however, there is insufficient evidence that these drugs benefit patients in the long term. Mechanical circulatory support (MCS) is a life support technology that was firstly used clinically in the 1950s. It can replace or partially replace the functions of the heart and/or lungs. And by increasing end-organ and coronary artery perfusion, reducing cardiac volume load, ventricular wall stress and myocardial oxygen consumption, etc. mechanism, quickly and accurately produce a stable hemodynamic effect, ultimately reducing the patient's pulmonary circulation congestion and myocardial ischemia. Reduce blood flow and infarction area and gain valuable time for follow-up treatment, so that patients with severe heart disease can be supported and transitioned to treatment great progress has been made in the treatment of heart diseases, and this technology has been widely used in the field of critical heart disease. 2017 American Heart Association The American Heart Association (AHA) recommends MCS for waiting for recovery of cardiac function or heart transplantation. Interimplantation and definitive treatment of advanced heart failure. Depending on location, MCS is divided into left ventricle Left ventricular assist device (LVAD), right ventricular assist device (Right ventricular assist device (RVAD), biventricular assist device (Biventricular assist device, BVAD) and total artificial heart (TAH). Currently, MCS commonly used in clinical practice mainly includes Intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (Extracorporeal membrane oxygenation (ECMO), Impella, TandemHeart and RVAD. The Impella system is an LVAD, it is divided into 3 models according to the diameter of the instrument: 12F (Impella 2.5), 14F (Impella CP) and 21F (Impella 5.0), the corresponding maximum output flows are 2.5L/min, 3.0~4.0L/min and 5.0L/min. The working principle of the device is to pump the left heart through the built-in micro axial flow pump at the front end of the catheter.
The oxygenated blood in the ventricle is pumped out through the catheter inlet, and then the axial flow pump is pumped directly into the ascending aorta to establish the left ventricular-ascending aorta. Aortic drainage pathway. Can help increase cardiac output (CO), increase aortic pressure and Coronary perfusion pressure, improve mean arterial pressure, coronary blood flow; while reducing left ventricular preload and pulmonary Pulse wedge pressure reduces ventricular wall tension and myocardial oxygen consumption. Acts as an active mechanical pump and partially replaces left ventricular function able. Impella is commonly used in the clinical treatment of cardiogenic shock. The ISAR-SHOCK study enrolled 26 patients with acute cardiac arrest. Comparing the efficacy of IABP and Impella 2.5 in patients with cardiogenic shock after myocardial infarction, the primary endpoint of the study Changes in cardiac index (CI) 30 minutes after MCS insertion. It was found that Impella A more significant increase in CI than after IABP, with 30-day mortality of 46% in both groups, confirms that Impella 2.5 Safety and feasibility in the treatment of cardiogenic shock after acute myocardial infarction. Two other studies also found that Similar conclusion RECOVER I study is a study that included 16 cases of cardiogenic shock or hypocardia after cardiotomy. A prospective, single-arm study of patients with displacement syndrome, the results of which indicate immediate blood loss after implantation of Impella 5.0 Fluid dynamics indicators improved significantly, and 93% of patients had improved cardiac function at discharge, with all patients at 30 days, 3 months, and 1 year. The survival rates were 94%, 81% and 75% respectively, proving the safety of Impella 5.0 for bridging treatment after cardiac surgery and feasibility. Currently, only Impella produced by the American company Abiomed has been approved by the FDA. However, imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling Bionic Technology Co., Ltd. has developed an interventional left ventricular assist system. The test device was tested in preclinical animals It has shown good effectiveness and safety. Through the implementation of this clinical trial, the interventional left ventricular assist system The safety and effectiveness of the system for hemodynamic support in patients with cardiogenic shock have led to further development of this product in the country.
- Conditions
- Cardiogenic Shock
- Being tested
- Interventional Left Ventricular Assist System
- Medical subject headings
- Shock, Cardiogenic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Interventional Left Ventricular Assist SystemDevice
Interventional left ventricular assist system for cardiogenic shock patients
| Study group | Role | What they receive |
|---|---|---|
| Interventional Left Ventricular Assist System Pre-trial | Experimental | The design of the first phase pre-trial clinical study will involve a total of 6 subjects. The survival rate of subjects before discharge or 30 days after weaning was the main effectiveness evaluation indicator, and the safety and effectiveness of the test device were preliminarily evaluated. All SAE events during the study will be reviewed by CEC experts. According to the expert review opinions, if no unexpected serious complications and product defects are found, the Formal Research phase will be started. Receives: Device: Interventional Left Ventricular Assist System |
| Interventional Left Ventricular Assist System Formal Research | Experimental | A formal clinical trial to evaluate the effectiveness and safety of interventional left ventricular assist system for hemodynamic support in patients with cardiogenic shock through a prospective, multicenter, single-group target value study.The total number of patients enrolled in this study is planned to be 54. This sample size is calculated according to statistical principles, combining the research hypothesis and the estimate of the expected level of efficacy. The sample size calculation is based on the main efficacy index and the main safety index. Since it is set according to the common evaluation index, the sample size is calculated for the two main evaluation indicators separately, and the largest one is used as the final sample size of this trial. Receives: Device: Interventional Left Ventricular Assist System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival rate of subjects at discharge or 30 days after weaning from ventilator (whichever is longer)
Survival was defined as recovery of cardiac function or survival to bridging therapy; Recovery of cardiac function was defined as no need for any mechanical support or IABP assistance 30 days after removal of the invasive left ventricular assist system or at discharge (whichever was longer).
Survival to bridging therapy was defined as survival to the induction of anesthesia for heart transplantation or placement of an implantable ventricular assist device.
Measured: 30days
The incidence of major adverse events at discharge or 30 days after weaning (whichever is longer)
Major adverse events included death and stroke.
Measured: 30days
Secondary outcomes (2)
hemodynamic indicators
Immediately after surgery, before weaning, and 24 hours after weaning, researchers evaluated the improvement in the subjects' hemodynamics after implantation of the trial device. (cardiac index(L/min/m2), mean arterial pressure(mmHg), pulmonary diastolic pressure(mmHg))
Measured: 30days
Successful device placement and technical success
Successful device placement is defined as the successful placement of a disposable left ventricular catheter pump into the left ventricle via the artery, and the delivery system can be withdrawn smoothly.
Technical success: After successful placement of the test device, blood can be pumped from the left ventricle into the ascending aorta, increasing the subject's cardiac output.
Measured: 30days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2023
- Study start8 Nov 2023
- Primary completion8 Nov 2025 (estimated)
- Study completion8 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiogenic ShockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fujian Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Liang-Wan Chen MD, Fujian Medical University
- Investigators
- Liang-wan Chen, M.D Ph.D, Study chair, Fujian Medical University Union Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06127927
- Sponsor's protocol ID
- A202301
- Status last verified
- Jul 2024
- First submitted
- 8 Nov 2023
- Last updated
- 8 Jul 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation the Efficacy and Safety of an Interventional Left Ventricular Assist System for Hemodynamic Support in Patients With Cardiogenic Shock: A Prospective, Multicenter, Single-group Target Value Study of Sustained
- ClinicalTrials.gov ID
- NCT06127927
- Acronym / sponsor ID
- A202301
- Conditions
- Cardiogenic Shock
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Fujian Medical UniversityUniversity, hospital or other
- Study start
- 8 Nov 2023 (actual)
- Primary completion
- 8 Nov 2025 (estimated)
- Study completion
- 8 Dec 2025 (estimated)
- First posted
- 13 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling Bionic Technology Co., Ltd. has developed an interventional left ventricular assist system. The test device was tested in preclinical animals It has shown good effectiveness and safety. Through the implementation of this clinical trial, the interventional left ventricular assist system The safety and effectiveness of the system for hemodynamic support in patients with cardiogenic shock have led to further development of this product in the country.
Detailed description
In recent years, patients with severe heart disease, with coronary heart disease as the main disease spectrum, have been on the rise, and the mortality rate remains high. In routine clinical diagnosis and treatment, inotropic drugs and vasoactive drugs are used to correct shock and maintain blood flow. The cornerstone of mechanical stability, however, there is insufficient evidence that these drugs benefit patients in the long term. Mechanical circulatory support (MCS) is a life support technology that was firstly used clinically in the 1950s. It can replace or partially replace the functions of the heart and/or lungs. And by increasing end-organ and coronary artery perfusion, reducing cardiac volume load, ventricular wall stress and myocardial oxygen consumption, etc. mechanism, quickly and accurately produce a stable hemodynamic effect, ultimately reducing the patient's pulmonary circulation congestion and myocardial ischemia. Reduce blood flow and infarction area and gain valuable time for follow-up treatment, so that patients with severe heart disease can be supported and transitioned to treatment great progress has been made in the treatment of heart diseases, and this technology has been widely used in the field of critical heart disease. 2017 American Heart Association The American Heart Association (AHA) recommends MCS for waiting for recovery of cardiac function or heart transplantation. Interimplantation and definitive treatment of advanced heart failure. Depending on location, MCS is divided into left ventricle Left ventricular assist device (LVAD), right ventricular assist device (Right ventricular assist device (RVAD), biventricular assist device (Biventricular assist device, BVAD) and total artificial heart (TAH). Currently, MCS commonly used in clinical practice mainly includes Intra-aortic balloon pump (IABP), extracorporeal membrane oxygenation (Extracorporeal membrane oxygenation (ECMO), Impella, TandemHeart and RVAD. The Impella system is an LVAD, it is divided into 3 models according to the diameter of the instrument: 12F (Impella 2.5), 14F (Impella CP) and 21F (Impella 5.0), the corresponding maximum output flows are 2.5L/min, 3.0~4.0L/min and 5.0L/min. The working principle of the device is to pump the left heart through the built-in micro axial flow pump at the front end of the catheter.
The oxygenated blood in the ventricle is pumped out through the catheter inlet, and then the axial flow pump is pumped directly into the ascending aorta to establish the left ventricular-ascending aorta. Aortic drainage pathway. Can help increase cardiac output (CO), increase aortic pressure and Coronary perfusion pressure, improve mean arterial pressure, coronary blood flow; while reducing left ventricular preload and pulmonary Pulse wedge pressure reduces ventricular wall tension and myocardial oxygen consumption. Acts as an active mechanical pump and partially replaces left ventricular function able. Impella is commonly used in the clinical treatment of cardiogenic shock. The ISAR-SHOCK study enrolled 26 patients with acute cardiac arrest. Comparing the efficacy of IABP and Impella 2.5 in patients with cardiogenic shock after myocardial infarction, the primary endpoint of the study Changes in cardiac index (CI) 30 minutes after MCS insertion. It was found that Impella A more significant increase in CI than after IABP, with 30-day mortality of 46% in both groups, confirms that Impella 2.5 Safety and feasibility in the treatment of cardiogenic shock after acute myocardial infarction. Two other studies also found that Similar conclusion RECOVER I study is a study that included 16 cases of cardiogenic shock or hypocardia after cardiotomy. A prospective, single-arm study of patients with displacement syndrome, the results of which indicate immediate blood loss after implantation of Impella 5.0 Fluid dynamics indicators improved significantly, and 93% of patients had improved cardiac function at discharge, with all patients at 30 days, 3 months, and 1 year. The survival rates were 94%, 81% and 75% respectively, proving the safety of Impella 5.0 for bridging treatment after cardiac surgery and feasibility. Currently, only Impella produced by the American company Abiomed has been approved by the FDA. However, imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling Bionic Technology Co., Ltd. has developed an interventional left ventricular assist system. The test device was tested in preclinical animals It has shown good effectiveness and safety. Through the implementation of this clinical trial, the interventional left ventricular assist system The safety and effectiveness of the system for hemodynamic support in patients with cardiogenic shock have led to further development of this product in the country.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Interventional Left Ventricular Assist System Pre-trial | Experimental | Device: Interventional Left Ventricular Assist SystemThe design of the first phase pre-trial clinical study will involve a total of 6 subjects. The survival rate of subjects before discharge or 30 days after weaning was the main effectiveness evaluation indicator, and the safety and effectiveness of the test device were preliminarily evaluated. All SAE events during the study will be reviewed by CEC experts. According to the expert review opinions, if no unexpected serious complications and product defects are found, the Formal Research phase will be started. |
| Interventional Left Ventricular Assist System Formal Research | Experimental | Device: Interventional Left Ventricular Assist SystemA formal clinical trial to evaluate the effectiveness and safety of interventional left ventricular assist system for hemodynamic support in patients with cardiogenic shock through a prospective, multicenter, single-group target value study.The total number of patients enrolled in this study is planned to be 54. This sample size is calculated according to statistical principles, combining the research hypothesis and the estimate of the expected level of efficacy. The sample size calculation is based on the main efficacy index and the main safety index. Since it is set according to the common evaluation index, the sample size is calculated for the two main evaluation indicators separately, and the largest one is used as the final sample size of this trial. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age 18-75 years old;
- Refractory cardiogenic shock as determined by the cardiac MDT expert group; The criteria for refractory cardiogenic shock are: despite adequate doses of two vasoactive drugs and treatment of the underlying cause, there is still evidence of tissue hypoperfusion;
- The subject can understand the purpose of the trial, voluntarily participate and sign the written informed consent form reviewed and approved by the ethics committee; the subject agrees to complete the follow-up in accordance with the protocol requirements.
- Age 18-75 years old;
- Low cardiac output syndrome or increased filling pressure after regular continuous pumping of 1 high-dose or 2 medium-dose inotropic drugs within 48 hours after cardiopulmonary bypass was removed during cardiac surgery. The specific criteria are as follows;
Key exclusion criteria (50 listed)
- Right heart failure that meets any of the following conditions:
- a Central venous pressure-capillary wedge pressure ≥10mmHg; b Central venous pressure-pulmonary artery diastolic pressure ≥10mmHg; c Cardiac tamponade.
- Any peripheral vascular disease that prevents the placement of the trial device;
- Left or right ventricular thrombus;
- Aortic valve regurgitation, echocardiographic grade ≥2+;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Interventional Left Ventricular Assist SystemInterventional left ventricular assist system for cardiogenic shock patients | Device | Interventional Left Ventricular Assist System Formal Research, Interventional Left Ventricular Assist System Pre-trial |
Primary outcome
Survival rate of subjects at discharge or 30 days after weaning from ventilator (whichever is longer)
Time frame: 30days
Survival was defined as recovery of cardiac function or survival to bridging therapy; Recovery of cardiac function was defined as no need for any mechanical support or IABP assistance 30 days after removal of the invasive left ventricular assist system or at discharge (whichever was longer). Survival to bridging therapy was defined as survival to the induction of anesthesia for heart transplantation or placement of an implantable ventricular assist device.
The incidence of major adverse events at discharge or 30 days after weaning (whichever is longer)
Time frame: 30days
Major adverse events included death and stroke.
2 secondary outcomes
hemodynamic indicators
Time frame: 30days
Successful device placement and technical success
Time frame: 30days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Cardiogenic Shock
Not yet recruitingPhase 4
Capital Offload-Shock
Hypervolemia, Cardiogenic Shock
Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction (AMI)
RecruitingObservational study
Cardiogenic Shock Working Group Registry
Cardiogenic Shock
RecruitingObservational study
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
AMI Cardiogenic Shock
RecruitingObservational study
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
Heart Failure, Muscle Atrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Liang-wan Chen, M.D Ph.D study chair
Fujian Medical University Union Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Interventional Left Ventricular Assist System in people with Cardiogenic Shock, run by Fujian Medical University at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 50 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Liang-wan Chen, M.D Ph.D (+8613358255333, chenliangwan@tom.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival rate of subjects at discharge or 30 days after weaning from ventilator (whichever is longer) (time frame: 30days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2024.